Drug intelligence / Profile preview

benzodiazepines + buprenorphine

Development stage: Unknown
Modality: Small Molecules
Administration: Buccal, Injection, Intramuscular, Intravenous, Oral, Rectal, Subcutaneous, Sublingual

Overview

This represents a combination of two distinct drug classes rather than a single pharmaceutical product. Benzodiazepines (including medications like Valium, Xanax, and Klonopin) are sedative medications often prescribed for anxiety disorders. Buprenorphine is a partial opioid agonist medication used for treating opioid use disorder and pain management. When prescribed concurrently, this combination requires careful clinical consideration due to increased risks of respiratory depression and overdose.

Targets

KOR (Kappa opioid receptor)GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on benzodiazepines + buprenorphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benzodiazepines + buprenorphine.

Explore the full profile